Alpha Cognition Inc.
Alpha Cognition Inc. (ACOG): 12 pipeline candidates · 1 upcoming catalyst · ~15 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
14.9 months
D/E 0.21 · 1% dilution
Lead: Phase 1
12 candidates
1 upcoming, next in ~6975d
37 buys · 0 sells (180d)
A transparent, data-derived signal for Alpha Cognition Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$139.8M
Cash
$54.3M
Quarterly Burn
$11.8M
Runway
14.9 mo
Revenue
$3.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| ALPHA-0602 | Preclinical |
| ALPHA-0702 | Preclinical |
| ALPHA-0802 | Preclinical |
| ALPHA-1062 for acute pancreatitis | Preclinical |
| ALPHA-1062 in combination with memantine | Preclinical |
| ALPHA-1062 intranasal (ALPHA-1062IN) | Preclinical |
| ALPHA-1062 original nasal formulation (Phase I studies) | Phase 1 |
| alpha-1062 sublingual | Preclinical |
| ALPHA-1062 sublingual formulation | Preclinical |
| zunveyl | Phase 4 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
20
Total value held
$10.6M
| Holder | Shares | Value |
|---|---|---|
| sphera funds management ltd. | 567,616 | $3.1M |
| alyeska investment group, l.p. | 365,000 | $2.0M |
| boothbay fund management, llc | 256,393 | $1.4M |
| aristides capital llc | 218,510 | $1.2M |
| cantor fitzgerald, l. p. | 188,631 | $1.0M |
| citadel advisors llc | 89,589 | $492K |
| villere st denis j & co llc | 71,158 | $391K |
| tudor investment corp et al | 61,596 | $338K |
| act capital management, llc | 51,500 | $283K |
| berkshire asset management llc/pa | 19,824 | $109K |
Showing top 10 of 20 institutional holders of Alpha Cognition Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Alpha Cognition Inc.'s pipeline?
Alpha Cognition Inc. (ACOG) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Alpha Cognition Inc.'s lead drug candidate?
Alpha Cognition Inc.'s most advanced tracked candidate is ALPHA-0602 (Preclinical) for Treatment of amyotrophic lateral sclerosis (ALS).
What is Alpha Cognition Inc.'s next catalyst?
Alpha Cognition Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ZUNVEYL" — expected July 23, 2045.
What is Alpha Cognition Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Alpha Cognition Inc. has approximately 14.9 months of cash runway.
What is Alpha Cognition Inc.'s market capitalization?
Alpha Cognition Inc.'s market capitalization is approximately $139.8M.
Get the full picture on Alpha Cognition Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.